Published in Lab Law Weekly, January 19th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Alnylam Pharmaceuticals.
Report 1: Alnylam Pharmaceuticals, Inc., (ALNY) has initiated a human experimental infection study with respiratory syncytial virus (RSV) designed to establish a safe and reliable RSV infection of the upper respiratory tract in adult volunteers.
Upon determination of the optimal level of RSV inoculum, Alnylam plans to initiate a subsequent clinical protocol to evaluate the anti-viral activity for ALN-RSV01, an RNAi therapeutic being developed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly